We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Nabriva Therapeutics announced in a post-hoc analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 trials by age, XENLETA™ (lefamulin) demonstrated consistently high efficacy and similar safety and tolerability profiles across all ...
Nabriva Therapeutics announced the European Commission (EC) has issued a legally binding decision for approval of the marketing authorization application for XENLETA™ (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults ...
Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections ...